reports
Lumos Pharma and Double Point Ventures Announce Successful Completion ...
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable t...
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sust...
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the , or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. “The new analyses and updated data from our Phase 2 OraGrow...
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at...
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024 AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the , or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Defi...
Lumos Pharma Enters into Definitive Merger Agreement with Double Point...
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 2...
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the ...
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the , or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for...
Lumos Pharma Announces Abstract Accepted for Presentation at September...
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024 AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile. Abstract Presentation: Friday, September 13th – E-poster Session ...
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Inve...
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th Ti...
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provide...
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 3...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provi...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared re...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Pres...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the , held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024. “The new analyses of data from our OraGrowtH212 Trial further characterized LUM-201’s unique ability to augment the nat...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 202...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the , to be held in Boston, MA June 1-4, 2024. Poster Session P069 – Monday June 3, 12:00-1:30 PM ET : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Ho...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Re...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therap...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provid...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. ...
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming...
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe. Pediatric Endocrine Society () Annual Meeting, held May 2-5, 2024, in Chicago, IL Abstract, OraGrowtH210 Trial (P...
Lumos Pharma Announces that the USPTO Has Granted Patent Protection fo...
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.” This...
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Cli...
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” Pitukcheewanont, MD, Appointed Chief Medical Officer Conference Call Today at 4:30 PM EST AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company advancing an oral therapeuti...
Lumos Pharma to Report Full Year 2023 Financial Results and Host Confe...
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A que...
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Li...
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual one-on-one meetings with the investment community on Wednesday, February 14 during the event. ...
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medica...
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and regulatory strategy, and he will continue to oversee medical affairs as the Company prepares to initiate its ...
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Pha...
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency Webinar to be Held December 6, 2023 at 1:30pm EST AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.